Latest Breaking News On - Nicola mikulcik - Page 1 : comparemela.com

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Saudi arabiaUnited statesFormycon biosimilarNicola mikulcikKlinge biopharma gmbhKlinge biopharmaInvestor relations corporate communicationsEuropean medicines agencyAlira healthDrug administrationGenentech incRegeneron pharmaceuticals incFrankfurt stock exchangePresse releaseBiosimilar candidateMiddle east

Formycon hosts conference call on the results of the first quarter 2024

EQS-News: Formycon AG / Key word: Quarterly / Interim Statement/Conference Formycon hosts conference call on the results of the first quarter 2024 02.05.2024 / 07:30.

New yorkUnited statesStefan glombitzaAndreas seidlHauck aufhNicola mikulcikFrankfurt stock exchangeInvestor relations corporate communicationsEquity forum spring conferenceResearch roundtablePress releaseExecutive boardForum spring conferenceEnno spillnerInvestor relationsCorporate communications

Formycon invites to the conference call on the results of the financial year 2023 and announces part

EQS-News: Formycon AG / Key word(s): Conference/Annual ResultsFormycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 22.04.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of t.

United statesNew yorkStefan glombitzaAndreas seidlNicola mikulcikHauck aufhEquity forum spring conferenceDistribution servicesFrankfurt stock exchangeResearch roundtableInvestor relations corporate communicationsAnnual resultsExecutive boardEnno spillnerForum spring conferenceInvestor relations

Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024

EQS-News: Formycon AG / Key word: Conference/Annual Results Formycon invites to the conference call on the results of the financial year 2023 and announces participation in.

New yorkUnited statesHauck aufhNicola mikulcikStefan glombitzaAndreas seidlEquity forum spring conferenceResearch roundtableFrankfurt stock exchangeInvestor relations corporate communicationsPress releaseExecutive boardEnno spillnerForum spring conferenceInvestor relationsCorporate communications

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (

EQS-News: Formycon AG / Key word(s): Market LaunchFormycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) 11.04.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press release // April 11, 2024 Formycon announces co.

United kingdomUnited statesJennifer pereiraNicola mikulcikLarissa monizDistribution servicesTeva canadaPolpharma biologics groupGenentech incTeva pharmaceuticalsHealth canadaTeva pharmaceutical industries ltdInvestor relations corporate communicationsFrankfurt stock exchangeMarket launchNorth america